Georgia Blood Cancer Trials Network
The Georgia Blood Cancer Trials Network collaborates with oncology practices, cancer centers and hospitals across Georgia to enhance accessibility to clinical trials for patients with blood cancer.
Overview
The Georgia Blood Cancer Trials Network (BCTN) aims to improve clinical trial participation for diverse populations of patients by opening both therapeutic and non-therapeutic clinical trials in communities across the state.
The goal of the network is to make innovative therapies more accessible to patients with blood cancer, particularly those residing in rural and high-poverty areas. It is supported by grants from The Leukemia & Lymphoma Society and National Cancer Institute and includes the Georgia Center for Oncology Research & Education (Georgia CORE) as a partner.
Network partners offering access to clinical trials are located in a number of communities across the state of Georgia.
Network Trials at Winship
At Winship, our clinical researchers are conducting clinical trials that are part of the Georgia Blood Cancer Trials Network at multiple Winship locations.
View network clinical trials available at Winship:
Check back soon for available network clinical trials.
AHOD2131 | A Randomized Phase III Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Principal investigator: Pamela Allen, MD
ReVenG | Multicenter, Open-Label, Phase II Study to Evaluate the Efficacy and Safety of Venetoclax-Obinutuzumab Retreatment in Patients with Recurring Chronic Lymphocytic Leukemia*
Principal investigator: Andres Chang, MD
*Opening soon for accrual
A052101 | A Randomized Phase III Trial of Continuous vs. Intermittent Maintenance Therapy with Zanubrutinib as Upfront Treatment in Older Patients with Mantle Cell Lymphoma
Principal investigator: Jonathon Cohen, MD
S2308 | Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
Principal investigator: Kristie Blum, MD
SUCCESSOR-2 | A Phase III, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
Principal investigator: Nisha Joseph, MD
EAA173 | Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
Principal investigator: Nisha Joseph, MD
EXCALIBER-RRMM | A Phase III, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects With Relapsed or Refractory Multiple Myeloma
Principal investigator: Sagar Lonial, MD